Patterns of recurrence after ablation of colorectal cancer liver metastases

Ann Surg Oncol. 2012 Mar;19(3):834-41. doi: 10.1245/s10434-011-2048-x. Epub 2011 Aug 31.

Abstract

Purpose: To determine the local recurrence rate and factors associated with recurrence after intraoperative ablation of colorectal cancer liver metastases.

Methods: A retrospective analysis of a prospectively maintained database was performed for patients who underwent ablation of a hepatic colorectal cancer metastasis in the operating room from April 1996 to March 2010. Kaplan-Meier survival curves and Cox models were used to determine recurrence rates and assess significance.

Results: Ablation was performed in 10% (n = 158 patients) of all cases during the study period. Seventy-eight percent were performed in conjunction with a liver resection. Of the 315 tumors ablated, most tumors were ≤ 1 cm in maximum diameter (53%). Radiofrequency ablation was used to treat most of the tumors (70%). Thirty-six tumors (11%) had local recurrence as part of their recurrence pattern. Disease recurred in the liver or systemically after 212 tumors (67%) were ablated. On univariate analysis, tumor size greater than 1 cm was associated with a significantly increased risk of local recurrence (hazard ratio 2.3, 95% confidence interval 1.2-4.5, P = 0.013). The 2 year ablation zone recurrence-free survival was 92% for tumors ≤ 1 cm compared to 81% for tumors >1 cm. On multivariate analysis, tumor size of >1 cm, lack of postoperative chemotherapy, and use of cryotherapy were significantly associated with a higher local recurrence rate.

Conclusions: Intraoperative ablation appears to be highly effective treatment for hepatic colorectal tumors ≤ 1 cm.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Catheter Ablation*
  • Chemoradiotherapy, Adjuvant
  • Colorectal Neoplasms / pathology*
  • Female
  • Hepatectomy
  • Humans
  • Liver Neoplasms / mortality
  • Liver Neoplasms / secondary*
  • Liver Neoplasms / surgery*
  • Male
  • Middle Aged
  • Neoadjuvant Therapy
  • Neoplasm Recurrence, Local*
  • Survival Rate